Request Demo
Recent blog posts
Latest Hotspot
8 min read
ChiCTR2600122069 Albumin-Bound Paclitaxel Locally Advanced Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
ChiCTR2600122069 clinical trial report covering Albumin-Bound Paclitaxel, Phase 2, endpoints, sponsor, geography, readout timing and development white spac
Latest Hotspot
8 min read
ChiCTR2600122046 HLX-43 Advanced Pancreatic Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
ChiCTR2600122046 clinical trial report covering HLX-43, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600122034 Trastuzumab Ovarian Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
ChiCTR2600122034 clinical trial report covering Trastuzumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07518238 Bupivacaine liposome Brachydactyly, Type E Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07518238 clinical trial report covering Bupivacaine liposome, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07517653 Retlirafusp alfa Mucosal Melanoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07517653 clinical trial report covering Retlirafusp alfa, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07518602 Sintilimab Advanced Neuroendocrine Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07518602 clinical trial report covering Sintilimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07517640 Alflutinib Mesylate Non-small cell lung cancer stage I Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07517640 clinical trial report covering Alflutinib Mesylate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07516925 Ivonescimab Leiomyosarcoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07516925 clinical trial report covering Ivonescimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07517510 Omacetaxine Mepesuccinate Mixed phenotype acute leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07517510 clinical trial report covering Omacetaxine Mepesuccinate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07518485 Indocyanine Green Skin Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07518485 clinical trial report covering Indocyanine Green, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07517276 Tauroursodeoxycholate sodium Metabolic dysfunction-associated steatotic liver disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07517276 clinical trial report covering Tauroursodeoxycholate sodium, Phase 2, endpoints, sponsor, geography, readout timing and development white space
Latest Hotspot
8 min read
NCT07517185 Cladribine Multiple Sclerosis, Relapsing-Remitting Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07517185 clinical trial report covering Cladribine, Phase 2, endpoints, sponsor, geography, readout timing and development white space.